Skip to main content
SpringerLink
Log in
Book cover

Multiple Myeloma pp 1–14Cite as

ELDA qASO-PCR for High Sensitivity Detection of Tumor Cells in Bone Marrow and Peripheral Blood

  • Protocol
  • First Online:

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1792))

Abstract

A quantitative allele-specific polymerase chain reaction in combination with an extreme limiting dilution approach (ELDA qASO-PCR) enables the detection of tumor cells in patients with multiple myeloma (MM) in bone marrow (BM) samples and in peripheral blood (PB) with a sensitivity of <10−6. The two-step procedure of patient-specific tumor cell identification via the immunoglobulin heavy chain (IgH) and kappa/lambda light chain (k/λ LC) locus, followed by tumor cells quantification by ELDA qASO-PCR allows for the application of this method to the majority of MM patients, including those with Bence Jones proteinuria.

This is a preview of subscription content, log in via an institution.

Protocol
USD   49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Springer Nature is developing a new tool to find and evaluate Protocols. Learn more

References

  1. Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Blade J, Mateos MV, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar SV, San Miguel J, Avet-Loiseau H (2016) International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17(8):e328–e346. https://doi.org/10.1016/S1470-2045(16)30206-6

    Article  PubMed  Google Scholar 

  2. Paiva B, Vidriales MB, Cervero J, Mateo G, Perez JJ, Montalban MA, Sureda A, Montejano L, Gutierrez NC, Garcia de Coca A, de Las Heras N, Mateos MV, Lopez-Berges MC, Garcia-Boyero R, Galende J, Hernandez J, Palomera L, Carrera D, Martinez R, de la Rubia J, Martin A, Blade J, Lahuerta JJ, Orfao A, San Miguel JF, Groups GPCS (2008) Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 112(10):4017–4023. https://doi.org/10.1182/blood-2008-05-159624

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Rawstron AC, Child JA, de Tute RM, Davies FE, Gregory WM, Bell SE, Szubert AJ, Navarro-Coy N, Drayson MT, Feyler S, Ross FM, Cook G, Jackson GH, Morgan GJ, Owen RG (2013) Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol 31(20):2540–2547. https://doi.org/10.1200/JCO.2012.46.2119

    Article  PubMed  Google Scholar 

  4. Korde N, Zingone A, Kwok ML, Manasanch EE, Bhutani M, Tageja N, Kazandjian D, Mailankody S, Costello R, Zhang Y, Burton D, Carter G, Wu P, Mulquin M, Zuchlinski D, Maric I, Calvo KR, Braylan RC, Roschewski M, Yuan C, Stetler-Stevenson M, Arthur DC, Lindenberg L, Kurdziel K, Choyke P, Steinberg SM, Landgren O (2013) Phase II clinical and correlative study of carfilzomib, lenalidomide, and dexamethasone followed by lenalidomide extended dosing (CRD-R) induces high rates of MRD negativity in newly diagnosed multiple myeloma (MM) patients. Blood 122(21)

    Google Scholar 

  5. Sherrod AM, Hari P, Mosse CA, Walker RC, Cornell RF (2015) Minimal residual disease testing after stem cell transplantation for multiple myeloma. Bone Marrow Transplant. https://doi.org/10.1038/bmt.2015.164

  6. Avet-Loiseau H, Corre J, Lauwers-Cances V, Chretien M-L, Robillard N, Leleu X, Hulin C, Gentil C, Arnulf B, Belhadj K, Brechignac S, Garderet L, Karlin L, Marit G, Benboubker L, Orsini-Piocelle F, Royer B, Drenou B, Tiab M, Lamy T, MACRO M, Richardson PG, Anderson KC, Faham M, Facon T, Moreau P, Attal M, Munshi NC (2015) Evaluation of minimal residual disease (MRD) by next generation sequencing (NGS) is highly predictive of progression free survival in the IFM/DFCI 2009 trial. Blood 126(23):191

    Article  Google Scholar 

  7. Martinez-Lopez J, Lahuerta JJ, Pepin F, Gonzalez M, Barrio S, Ayala R, Puig N, Montalban MA, Paiva B, Weng L, Jimenez C, Sopena M, Moorhead M, Cedena T, Rapado I, Mateos MV, Rosinol L, Oriol A, Blanchard MJ, Martinez R, Blade J, San Miguel J, Faham M, Garcia-Sanz R (2014) Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood 123(20):3073–3079. https://doi.org/10.1182/blood-2014-01-550020

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Hose D, Reme T, Meissner T, Moreaux J, Seckinger A, Lewis J, Benes V, Benner A, Hundemer M, Hielscher T, Shaughnessy JD Jr, Barlogie B, Neben K, Kramer A, Hillengass J, Bertsch U, Jauch A, De Vos J, Rossi JF, Mohler T, Blake J, Zimmermann J, Klein B, Goldschmidt H (2009) Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. Blood 113(18):4331–4340. https://doi.org/10.1182/blood-2008-09-178350

    Article  CAS  PubMed  Google Scholar 

  9. Kumar S, Stecher G, Tamura K (2016) MEGA7: molecular evolutionary genetics analysis version 7.0 for bigger datasets. Mol Biol Evol 33(7):1870–1874. https://doi.org/10.1093/molbev/msw054

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Retter I, Althaus HH, Munch R, Muller W (2005) VBASE2, an integrative V gene database. Nucleic Acids Res 33(Database issue):D671–D674. https://doi.org/10.1093/nar/gki088

    Article  CAS  PubMed  Google Scholar 

  11. Cremer FW, Ehrbrecht E, Kiel K, Benner A, Hegenbart U, Ho AD, Goldschmidt H, Moos M (2000) Evaluation of the kinetics of the bone marrow tumor load in the course of sequential high-dose therapy assessed by quantitative PCR as a predictive parameter in patients with multiple myeloma. Bone Marrow Transplant 26(8):851–858. https://doi.org/10.1038/sj.bmt.1702628

    Article  CAS  PubMed  Google Scholar 

  12. Hu Y, Smyth GK (2009) ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods 347(1–2):70–78. https://doi.org/10.1016/j.jim.2009.06.008

    Article  CAS  PubMed  Google Scholar 

  13. Helsel DR (2005) Nondectects and data analysis; statistics for censored environmental data. John Wiley and Sons, Hoboken, NJ

    Google Scholar 

Download references

Acknowledgments

We thank Manfed Küpper for his assistance in the design of the consensus primers for k/λ loci.

Author information

Authors and Affiliations

  1. Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany

    Stefanie Huhn

Authors
  1. Stefanie Huhn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stefanie Huhn .

Editor information

Editors and Affiliations

  1. Janssen R&D, Spring House, PA, USA

    Christoph Heuck

  2. The Myeloma Institute, University of Arkansas for Medical Science, Little Rock, AR, USA

    Niels Weinhold

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Science+Business Media, LLC, part of Springer Nature

About this protocol

Check for updates. Verify currency and authenticity via CrossMark

Cite this protocol

Huhn, S. (2018). ELDA qASO-PCR for High Sensitivity Detection of Tumor Cells in Bone Marrow and Peripheral Blood. In: Heuck, C., Weinhold, N. (eds) Multiple Myeloma. Methods in Molecular Biology, vol 1792. Humana, New York, NY. https://doi.org/10.1007/978-1-4939-7865-6_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-7865-6_1

  • Published:

  • Publisher Name: Humana, New York, NY

  • Print ISBN: 978-1-4939-7864-9

  • Online ISBN: 978-1-4939-7865-6

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation